ArticleOncology letters2018
The LINC01186 suppresses cell proliferation and invasion ability in papillary thyroid carcinoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Long non-coding RNAs and signaling networks in non-small cell lung cancer: mechanistic insights into tumor pathogenesis.Cancer gene therapy · 2025Review
- SIRT7 affects the proliferation and apoptosis of papillary thyroid cancer cells by desuccinylation of LATS1.BMC cancer · 2025Article
- The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.International journal of molecular sciences · 2024Article
- Emodin treatment of papillary thyroid cancer cell linesOncology letters · 2023Article
- Crosstalk between YY1 and lncRNAs in cancer: A review.Medicine · 2022Review
- HIF-1α and Caspase-3 expression in aggressive papillary thyroid carcinoma.World journal of surgical oncology · 2022Article
- SALIS transcriptionally represses IGFBP3/Caspase-7-mediated apoptosis by associating with STAT5A to promote hepatocellular carcinoma.Cell death & disease · 2022Article
- Therapeutic potential of extracellular vesicle-associated long noncoding RNA.Bioengineering & translational medicine · 2020Review
- Long non-coding RNA BRM promotes proliferation and invasion of papillary thyroid carcinoma by regulating the microRNA-331-3p/SLC25A1 axis.Oncology letters · 2020Article
- [High expression of DNMT3B promotes proliferation and invasion of hepatocellular carcinoma cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Long non coding RNAs (lncRNAs) have been involved in regulating tumor progression including PTC. In the present study, we demonstrated that long non coding RNA LINC01186 was significantly downregulated in PTC tissue samples compared with adjacent normal tissue samples in patients. LINC01186 expression was also found to be higher in PTC cells. Lower LINC01186 expression was associated with lymph node metastasis of PTC patients. Functionally, LINC01186 overexpression significantly suppressed cell proliferation, cell colony formation and cell invasion ability in TPC-1 and IHH-4 cells. In addition, we demonstrated that LINC01186 overexpression inhibited large tumor suppressor kinase 1 (LATS1)/YY1 associated protein 1 (YAP) signaling by reducing YAP1 expression, while increasing LATS1 expression in TPC-1 and IHH-4 cells. Collectively, our data suggested that LINC01186 may serve as a potential target for therapy in thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.